Modulation of β-amyloid by a single dose of GSK933776 in patients with mild Alzheimer's disease: A phase i study

Alzheimer's Research and Therapy

Volumn 6, Issue 2, 2014, Pages

  Leyhe, Thomas ^a,b   Andreasen, Niels ^c   Simeoni, Monica ^d   Reich, Arno ^e   Von Arnim, Christine A F ^f   Tong, Xin ^d   Yeo, Astrid ^d   Khan, Shahid ^d   Loercher, Amy ^g   Chalker, Michelle ^d   Hottenstein, Charles ^g   Zetterberg, Henrik ^h,i   Hilpert, Jan ^j   Mistry, Prafull ^k  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY OF BASEL   (Switzerland)

^c KAROLINSKA INSTITUTE   (Sweden)

^d GLAXOSMITHKLINE   (United Kingdom)

^e UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^f UNIVERSITY OF ULM   (Germany)

^g GLAXOSMITHKLINE   (United States)

^h UNIVERSITY OF GOTHENBURG   (Sweden)

ⁱ UNIVERSITY COLLEGE LONDON   (United Kingdom)

^j Global Clinical Safety and Pharmacovigilance GlaxoSmithKline ^*  (United States)

^k Quante   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; GSK 933776; MONOCLONAL ANTIBODY; TAU PROTEIN; UNCLASSIFIED DRUG; AMYLOID BETA PROTEIN ANTIBODY; AMYLOID BETA PROTEIN[18-35]; AMYLOID BETA PROTEIN[28-42];

ADULT; AGED; ALZHEIMER DISEASE; AREA UNDER THE CURVE; ARTICLE; BACKACHE; CATHETERIZATION; CEREBROSPINAL FLUID; DOSE RESPONSE; DRUG EFFECT; DRUG HALF LIFE; DRUG SAFETY; EXPERIMENTAL MEDICINE; FATIGUE; FEMALE; HEADACHE; HEART ATRIUM FIBRILLATION; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; MILD COGNITIVE IMPAIRMENT; MINOR SURGERY; NAUSEA; NECK PAIN; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PLASMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RHINOPHARYNGITIS; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; UNSPECIFIED SIDE EFFECT; VOMITING; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; PHARMACODYNAMICS; PROTEIN CEREBROSPINAL FLUID LEVEL;

EID: 84901049049     PISSN: None     EISSN: 17589193     Source Type: Journal    
DOI: 10.1186/alzrt249     Document Type: Article

References (17)

1. Alzheimer's disease: genes, proteins, and therapy. Selkoe DJ, Physiol Rev 2001 81 741 766 11274343 (Pubitemid 32267077)
2. Life imitates art: anti-amyloid antibodies and inflammatory cerebral amyloid angiopathy. Greenberg SM, Frosch MP, Neurology 2011 76 772 773 10.1212/WNL.0b013e31820e7bce 21357829
3. Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease. DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM, Proc Natl Acad Sci U S A 2001 98 8850 8855 10.1073/pnas.151261398 11438712 (Pubitemid 32678116)
4. Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Ostrowitzki S, Deptula D, Thurfjell L, Barkhof F, Bohrmann B, Brooks DJ, Klunk WE, Ashford E, Yoo K, Xu ZX, Loetscher H, Santarelli L, Arch Neurol 2012 69 198 207 10.1001/archneurol.2011.1538 21987394
5. Safety and biomarker effects of solanezumab in patients with Alzheimer's disease. Farlow M, Arnold SE, van Dyck CH, Aisen PS, Snider BJ, Porsteinsson AP, Friedrich S, Dean RA, Gonzales C, Sethuraman G, DeMattos RB, Mohs R, Paul SM, Siemers ER, Alzheimers Dement 2012 8 261 271 10.1016/j.jalz.2011.09.224 22672770
6. A γ-secretase inhibitor decreases amyloid-β production in the central nervous system. Bateman RJ, Siemers ER, Mawuenyega KG, Wen G, Browning KR, Sigurdson WC, Yarasheski KE, Friedrich SW, Demattos RB, May PC, Paul SM, Holtzman DM, Ann Neurol 2009 66 48 54 10.1002/ana.21623 19360898
7. Decreased clearance of CNS β-amyloid in Alzheimer's disease. Mawuenyega KG, Sigurdson W, Ovod V, Munsell L, Kasten T, Morris JC, Yarasheski KE, Bateman RJ, Science 2010 330 1774 10.1126/science.1197623 21148344
8. "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. Folstein MF, Folstein SE, McHugh PR, J Psych Research 1975 12 189 198 10.1016/0022-3956(75)90026-6
9. Tau and Aβ42 in cerebrospinal fluid from healthy adults 21-93 years of age: establishment of reference values. Sjögren M, Vanderstichele H, Agren H, Zachrisson I, Edsbagge M, Wikkelsø C, Skoog I, Wallin A, Wahlund LO, Marcusson J, Nägga K, Andreasen N, Davidsson P, Vanmechelen E, Blennow K, Clin Chem 2001 47 1776 1781 11568086 (Pubitemid 32881189)
10. Cerebrospinal fluid markers for prediction of Alzheimer's disease. Zetterberg H, Wahlund LO, Blennow K, Neurosci Lett 2003 352 67 69 10.1016/j.neulet.2003.08.011 14615052 (Pubitemid 37412328)
11. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Dubois B, Feldman HH, Jacova C, DeKosky ST, Barberger-Gateau P, Cummings J, Delacourte A, Galasko D, Gauthier S, Jicha G, Meguro K, O'Brien J, Pasquier F, Robert P, Rossor M, Salloway S, Stern Y, Visser PJ, Scheltens P, Lancet Neurol 2007 6 734 746 10.1016/S1474-4422(07)70178-3 17616482 (Pubitemid 47058377)
12. Revising the definition of Alzheimer's disease: a new lexicon. Dubois B, Feldman HH, Jacova C, Cummings JL, DeKosky ST, Barberger-Gateau P, Delacourte A, Frisoni G, Fox NC, Galasko D, Gauthier S, Hampel H, Jicha GA, Meguro K, O'Brien J, Pasquier F, Robert P, Rossor M, Salloway S, Sarazin M, de Souza LC, Stern Y, Visser PJ, Scheltens P, Lancet Neurol 2010 9 1118 1127 10.1016/S1474-4422(10) 70223-4 20934914
13. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, Gamst A, Holtzman DM, Jagust WJ, Petersen RC, Snyder PJ, Carrillo MC, Thies B, Phelps CH, Alzheimers Dement 2011 7 270 279 10.1016/j.jalz.2011.03.008 21514249
14. Effects of age and amyloid deposition on Aβ dynamics in the human central nervous system. Huang Y, Potter R, Sigurdson W, Santacruz A, Shih S, Ju YE, Kasten T, Morris JC, Mintun M, Duntley S, Bateman RJ, Arch Neurol 2012 69 51 58 10.1001/archneurol.2011.235 21911660
15. Idiopathic normal-pressure hydrocephalus: pathophysiology and diagnosis by CSF biomarkers. Jeppsson A, Zetterberg H, Blennow K, Wikkelsø C, Neurology 2013 80 1385 1392 10.1212/WNL.0b013e31828c2fda 23486875
16. Safety and changes in plasma cerebrospinal fluid amyloid β after a single administration of an amyloid β monoclonal antibody in subjects with Alzheimer disease. Siemers ER, Friedrich S, Dean RA, Gonzales CR, Farlow MR, Paul SM, Demattos RB, Clin Neuropharmacol 2010 33 67 73 10.1097/WNF. 0b013e3181cb577a 20375655
17. Apolipoprotein E 4 prevalence in Alzheimer's disease patients varies across global populations: a systematic literature review and meta-analysis. Crean S, Ward A, Mercaldi CJ, Collins JM, Cook MN, Baker NL, Arrighi HM, Dement Geriatr Cogn Disord 2011 31 20 30 10.1159/000321984 21124030